Top

Published in:

01-09-2016 | CANCER

Analgesic use and the risk of primary adult brain tumor

Authors: Kathleen M. Egan, Louis B. Nabors, Zachary J. Thompson, Carrie M. Rozmeski, Gabriella A. Anic, Jeffrey J. Olson, Renato V. LaRocca, Sajeel A. Chowdhary, Peter A. Forsyth, Reid C. Thompson

Published in: European Journal of Epidemiology | Issue 9/2016

Abstract

Glioma and meningioma are uncommon tumors of the brain with few known risk factors. Regular use of aspirin has been linked to a lower risk of gastrointestinal and other cancers, though evidence for an association with brain tumors is mixed. We examined the association of aspirin and other analgesics with the risk of glioma and meningioma in a large US case–control study. Cases were persons recently diagnosed with glioma or meningioma and treated at medical centers in the southeastern US. Controls were persons sampled from the same communities as the cases combined with friends and other associates of the cases. Information on past use of analgesics (aspirin, other anti-inflammatory agents, and acetaminophen) was collected in structured interviews. Logistic regression was used to estimate odds ratios (ORs) and 95 % confidence intervals (CIs) for analgesic use adjusted for potential confounders. All associations were considered according to indication for use. A total of 1123 glioma cases, 310 meningioma cases and 1296 controls were included in the analysis. For indications other than headache, glioma cases were less likely than controls to report regular use of aspirin (OR 0.69; CI 0.56, 0.87), in a dose-dependent manner (P trend < 0.001). No significant associations were observed with other analgesics for glioma, or any class of pain reliever for meningioma. Results suggest that regular aspirin use may reduce incidence of glioma.

Siegel R, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi:10.3322/caac.21332.CrossRefPubMed

Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103(9):714–36. doi:10.1093/jnci/djr077.CrossRefPubMedPubMedCentral

Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol. 2007;25(26):4127–36. doi:10.1200/JCO.2007.11.8554.CrossRefPubMed

Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-oncology. 2012;14(Suppl 5):v1–49. doi:10.1093/neuonc/nos218.CrossRefPubMedPubMedCentral

Fang Z, Kulldorff M, Gregorio DI. Brain cancer mortality in the United States, 1986 to 1995: a geographic analysis. Neuro-oncology. 2004;6(3):179–87. doi:10.1215/S1152851703000450.CrossRefPubMedPubMedCentral

Shete S, Hosking FJ, Robertson LB, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41(8):899–904. doi:10.1038/ng.407.CrossRefPubMedPubMedCentral

Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009;41(8):905–8. doi:10.1038/ng.408.CrossRefPubMedPubMedCentral

Dobbins SE, Broderick P, Melin B, et al. Common variation at 10p12.31 near MLLT10 influences meningioma risk. Nat Genet. 2011;43(9):825–7. doi:10.1038/ng.879.CrossRef

Braganza MZ, Kitahara CM, de Gonzalez AB, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro-oncology. 2012;14(11):1316–24. doi:10.1093/neuonc/nos208.CrossRefPubMedPubMedCentral

10.

Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nature reviews. Clin Oncol. 2012;9(5):259–67. doi:10.1038/nrclinonc.2011.199.

11.

Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30(3):377–86. doi:10.1093/carcin/bgp014.CrossRefPubMed

12.

Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med. 2007;58:239–52. doi:10.1146/annurev.med.57.121304.131253.CrossRefPubMed

13.

Joki T, Heese O, Nikas DC, et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 2000;60(17):4926–31.PubMed

14.

Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001;61(11):4375–81.PubMed

15.

Prayson RA, Castilla EA, Vogelbaum MA, Barnett GH. Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme. Ann Diagn Pathol. 2002;6(3):148–53.CrossRefPubMed

16.

Castilla EA, Prayson RA, Kanner AA, et al. Cyclooxygenase-2 in oligodendroglial neoplasms. Cancer. 2003;98(7):1465–72. doi:10.1002/cncr.11632.CrossRefPubMed

17.

Perdiki M, Korkolopoulou P, Thymara I, et al. Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Mol Cell Biochem. 2007;295(1–2):75–83. doi:10.1007/s11010-006-9275-7.CrossRefPubMed

18.

Buccoliero AM, Caldarella A, Arganini L, et al. Cyclooxygenase-2 in oligodendroglioma: possible prognostic significance. Neuropathology. 2004;24(3):201–7.CrossRefPubMed

19.

Kokoglu E, Tuter Y, Sandikci KS, et al. Prostaglandin E2 levels in human brain tumor tissues and arachidonic acid levels in the plasma membrane of human brain tumors. Cancer Lett. 1998;132(1–2):17–21.CrossRefPubMed

20.

Loh JK, Hwang SL, Lieu AS, Huang TY, Howng SL. The alteration of prostaglandin E2 levels in patients with brain tumors before and after tumor removal. J Neurooncol. 2002;57(2):147–50.CrossRefPubMed

21.

Rolle CE, Sengupta S, Lesniak MS. Mechanisms of immune evasion by gliomas. Adv Exp Med Biol. 2012;746:53–76. doi:10.1007/978-1-4614-3146-6_5.CrossRefPubMed

22.

Xu K, Shu HK. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res. 2007;67(13):6121–9. doi:10.1158/0008-5472.CAN-07-0141.CrossRefPubMed

23.

Wakimoto N, Wolf I, Yin D, et al. Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. Cancer Res. 2008;68(17):6978–86. doi:10.1158/0008-5472.CAN-07-5675.CrossRefPubMed

24.

Sareddy GR, Geeviman K, Ramulu C, Babu PP. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-kappaB pathway. J Neuro Oncol. 2012;106(1):99–109. doi:10.1007/s11060-011-0662-x.

25.

Kardosh A, Blumenthal M, Wang WJ, Chen TC, Schonthal AH. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther. 2004;3(1):55–62.CrossRefPubMed

26.

Tai HH, Chi X, Tong M. Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs). Prostaglandins Other Lipid Mediat. 2011;96(1–4):37–40. doi:10.1016/j.prostaglandins.2011.06.005.CrossRefPubMed

27.

Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41. doi:10.1016/S0140-6736(10)62110-1.CrossRefPubMed

28.

Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294(1):47–55. doi:10.1001/jama.294.1.47.CrossRefPubMed

29.

Sivak-Sears NR, Schwartzbaum JA, Miike R, Moghadassi M, Wrensch M. Case–control study of use of nonsteroidal antiinflammatory drugs and glioblastoma multiforme. Am J Epidemiol. 2004;159(12):1131–9. doi:10.1093/aje/kwh153.CrossRefPubMed

30.

Scheurer ME, El-Zein R, Thompson PA, et al. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomark Prev. 2008;17(5):1277–81. doi:10.1158/1055-9965.EPI-07-2621.CrossRef

31.

Scheurer ME, Amirian ES, Davlin SL, Rice T, Wrensch M, Bondy ML. Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies. Int J Cancer. 2011;129(9):2290–6. doi:10.1002/ijc.25883.CrossRefPubMedPubMedCentral

32.

Ferris JS, McCoy L, Neugut AI, Wrensch M, Lai R. HMG, CoA reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer. 2012;131(6):E1031–7. doi:10.1002/ijc.27536.CrossRefPubMedPubMedCentral

33.

Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004;24(5B):3177–84.PubMed

34.

Daugherty SE, Moore SC, Pfeiffer RM, et al. Nonsteroidal anti-inflammatory drugs and glioma in the NIH-AARP Diet and Health Study cohort. Cancer Prev Res. 2011;4(12):2027–34. doi:10.1158/1940-6207.CAPR-11-0274.CrossRef

35.

Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53(6):1322–7.PubMed

36.

Gaist D, Garcia-Rodriguez LA, Sorensen HT, Hallas J, Friis S. Use of low-dose aspirin and non-aspirin nonsteroidal anti-inflammatory drugs and risk of glioma: a case–control study. Br J Cancer. 2013;108(5):1189–94. doi:10.1038/bjc.2013.87.CrossRefPubMedPubMedCentral

37.

Bannon FJ, O’Rorke MA, Murray LJ, et al. Non-steroidal anti-inflammatory drug use and brain tumour risk: a case–control study within the Clinical Practice Research Datalink. CCC. 2013;. doi:10.1007/s10552-013-0279-9.PubMed

38.

Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003;88(5):684–8. doi:10.1038/sj.bjc.6600760.CrossRefPubMedPubMedCentral

39.

Anic GM, Madden MH, Sincich K, et al. Early life exposures and the risk of adult glioma. Eur J Epidemiol. 2013;28(9):753–8. doi:10.1007/s10654-013-9811-1.CrossRefPubMedPubMedCentral

40.

Horwitz RI, Feinstein AR. The problem of “protopathic bias” in case–control studies. Am J Med. 1980;68(2):255–8.CrossRefPubMed

41.

Schwartzbaum J, Jonsson F, Ahlbom A, et al. Prior hospitalization for epilepsy, diabetes, and stroke and subsequent glioma and meningioma risk. Cancer Epidemiol Biomark Prev. 2005;14(3):643–50. doi:10.1158/1055-9965.EPI-04-0119.CrossRef

42.

Culic V. Aspirin for preventing venous thromboembolism. N Engl J Med. 2013;368(8):772. doi:10.1056/NEJMc1215492#SA1.CrossRefPubMed

43.

Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA. 1968;61(1):46–52.CrossRefPubMedPubMedCentral

44.

Gasic GJ, Gasic TB, Murphy S. Anti-metastatic effect of aspirin. Lancet. 1972;2(7783):932–3.CrossRefPubMed

45.

Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006;55(1):115–22. doi:10.1136/gut.2004.047100.CrossRefPubMedPubMedCentral

46.

Doherty GA, Murray FE. Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age? Expert Opin Ther Targets. 2009;13(2):209–18. doi:10.1517/14728220802653631.CrossRefPubMed

47.

Hung WC. Anti-metastatic action of non-steroidal anti-inflammatory drugs. Kaohsiung J Med Sci. 2008;24(8):392–7. doi:10.1016/S1607-551X(08)70162-1.CrossRefPubMed

48.

Ruschoff J, Wallinger S, Dietmaier W, et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci USA. 1998;95(19):11301–6.CrossRefPubMedPubMedCentral

49.

McIlhatton MA, Tyler J, Burkholder S, et al. Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Res. 2007;67(22):10966–75. doi:10.1158/0008-5472.CAN-07-2562.CrossRefPubMed

50.

Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet. 2009;373(9671):1301–9. doi:10.1016/S0140-6736(09)60243-9.CrossRefPubMed

Title: Analgesic use and the risk of primary adult brain tumor
Authors: Kathleen M. Egan
Louis B. Nabors
Zachary J. Thompson
Carrie M. Rozmeski
Gabriella A. Anic
Jeffrey J. Olson
Renato V. LaRocca
Sajeel A. Chowdhary
Peter A. Forsyth
Reid C. Thompson
Publication date: 01-09-2016
Publisher: Springer Netherlands
Published in: European Journal of Epidemiology / Issue 9/2016
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-016-0129-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Analgesic use and the risk of primary adult brain tumor

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2016

Shedding light on the role of circadian disruption in breast cancer etiology

High body mass index and cancer risk—a Mendelian randomisation study

The Longitudinal Aging Study Amsterdam: cohort update 2016 and major findings

Overweight duration in older adults and cancer risk: a study of cohorts in Europe and the United States

Statin use and risk of glioma: population-based case–control analysis

Coffee consumption and the risk of cancer in the Norwegian Women and Cancer (NOWAC) Study